Filing Flows › UroGen Pharma (URGN) › Q2 2026
UroGen Pharma (URGN) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
UroGen Pharma (URGN) reported revenue of $72.5M for the second quarter 2026 (Q2 2026), +199% from a year earlier and +42% from the quarter before. Operating margin was 0.2%, net loss $14.4M (19.8% of revenue).
UroGen Pharma, Q2 2026: revenue $72.5M (+199% year over year), operating margin 0.2%, net loss $14.4M, operating cash flow −$33.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $72.5M | +42% | +199% |
| Operating profit | $111K | — | — |
| Net earnings | −$14.4M | — | — |
| Operating cash flow | −$33.0M | — | — |
What changed
Revenue was $72.5M in Q2 2026, up 199% year over year and up 42% from the previous quarter. Zusduri was the largest line at 70% of revenue. Jelmyto declined 9%.
Gross margin was 90.9%, up 5.6 points from Q2 2025. Operating profit was $111K, a 0.2% margin (up 171.3 points year over year). Operating expenses grew 6% against revenue growth of 199%. The fastest-growing cost line was SG&A (+12%). The quarter ended with a net loss of $14.4M, narrower than the previous quarter's $23.6M loss. Net interest and other expense of $8.8M was the main reason.
Operating cash flow was −$33.0M. Non-cash charges added back $100K of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items used $24.1M. Capital expenditures of $60K exceeded it, leaving free cash flow of −$33.1M.
Questions
What was UroGen Pharma's revenue in the second quarter 2026?
UroGen Pharma (URGN) reported revenue of $72.5M for the second quarter 2026 (Q2 2026), +199% from a year earlier and +42% from the quarter before.
Was UroGen Pharma profitable in the second quarter 2026?
Operating profit was $111K (0.2% of revenue) and net loss $14.4M.
Source: UroGen Pharma 10-Q on SEC EDGAR.